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Abstract The aim of this study was to explore the eﬀect
of long-term cross-sex hormonal treatment on cortical
and trabecular bone mineral density and main bio-
chemical parameters of bone metabolism in transsexu-
als. Twenty-four male-to-female (M-F) transsexuals and
15 female-to-male (F-M) transsexuals treated with either
an antiandrogen in combination with an estrogen or
parenteral testosterone were included in this cross-sec-
tional study. BMD was measured by DXA at distal
tibial diaphysis (TDIA) and epiphysis (TEPI), lumbar
spine (LS), total hip (HIP) and subregions, and whole
body (WB) and Z-scores determined for both the genetic
and the phenotypic gender. Biochemical parameters of
bone turnover, insulin-like growth factor-1 (IGF-1) and
sex hormone levels were measured in all patients. M-F
transsexuals were signiﬁcantly older, taller and heavier
than F-M transsexuals. They were treated by cross-sex
hormones during a median of 12.5 years before inclu-
sion. As compared with female age-matched controls,
they showed a signiﬁcantly higher median Z-score at
TDIA and WB (1.7±1.0 and 1.8±1.1, P<0.01) only.
Based on the WHO deﬁnition, ﬁve (who did not comply
with cross-sex hormone therapy) had osteoporosis. F-M
transsexuals were treated by cross-sex hormones during
a median of 7.6 years. They had signiﬁcantly higher
median Z-scores at TEPI, TDIA and WB compared
with female age-matched controls (+0.9±0.2 SD,
+1.0±0.4 SD and+1.4±0.3 SD, respectively, P<
0.0001 for all) and reached normal male levels except at
TEPI. They had signiﬁcantly higher testosterone and
IGF-1 levels (p<0.001) than M-F transsexuals. We
conclude that in M-F transsexuals, BMD is preserved
over a median of 12.5 years under antiandrogen and
estrogen combination therapy, while in F-M transsex-
uals BMD is preserved or, at sites rich in cortical bone, is
increased to normal male levels under a median of 7.6
years of androgen treatment in this cross sectional study.
IGF-1 could play a role in the mediation of the eﬀect of
androgens on bone in F-M transsexuals.
Keywords Bone mineral density (BMD) Æ DXA Æ
IGF-1 Æ Transsexuals
Introduction
Estrogens and androgens play important roles in skeletal
growth and in the maintenance of the adult bone mass
[1]. Sex hormone deﬁciency represents a major cause of
osteoporosis in both genders [2,3] and substitution of sex
steroids preserves or even increases bone mass in men
and women [4,5]. For obvious reasons, hormone sub-
stitution is usually based on the use of sex-matched
hormones [6,7,8,9]. Although there is increasing evi-
dence that cross-sex hormones, as physiologically pro-
duced in smaller amounts in both genders, do play a
certain role in the maintenance of skeletal homeostasis
[10], it is unclear whether in adults, cross-gender hor-
mone treatment may fully compensate for the lack of
genotypic gonadal hormones with respect to bone
health.
The diagnosis of ‘‘transsexualism’’, although explic-
itly classiﬁed in DSM-III-R (Diagnostic and Statistical
Manual of Mental Disorders), has been replaced by
‘‘gender identity disorder’’ in the DSM-IV. However,
transsexualism is included in the 10th revision of the
International Classiﬁcation of Diseases (ICD-10) and
persons aﬀected by this disorder refer to themselves as
transsexuals. Under these premises, this publication uses
the word transsexualism, referring to the gender identity
disorder. Transsexualism is a condition in which the
medical management of cross-sex reassignment is initi-
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ated and maintained using estrogen and antiandrogen
treatment in male-to-female (M-F) and androgen treat-
ment in female-to-male (F-M) transsexuals. Only a very
few studies have addressed the question whether BMD
in transsexuals is preserved while under cross-sex hor-
monal therapy and their results are rather conﬂicting
[11,12,13,14,15]. The only data on bone health in Cau-
casian transsexuals have been published by a Dutch
group [12,13,14,15,16]. One remaining report in the
world literature comes from Asia, investigating Singap-
orean F-M transsexuals [11].
Using histomorphometry from transiliac bone biop-
sies, Lips et al. observed a suppression of bone turnover
and a preservation of bone mass in both, M-F [12], and
F-M [13] transsexuals. Median duration on cross-sex
hormone treatment was 24 months in the former and 39
months in the latter study. Whereas mean bone mineral
density (BMD) of the lumbar spine remained unchanged
in F-M transsexuals, it increased slightly in M-F trans-
sexuals during 1 year of cross-gender hormone treat-
ment [14]. However, follow-up measurements in
subsamples of the above populations showed less
favorable results: whereas lumbar BMD was maintained
in the 20 M-F transsexuals after 32–63 months of cross-
sex hormone treatment, the 19 F-M transsexuals expe-
rienced signiﬁcant decreases in their lumbar BMD while
under androgen treatment for 28–53 months [15]. The
results of the Singaporean study are diﬃcult to interpret,
due to the short observation time, inhomogeneity with
respect to gonadectomy, unknown compliance with
hormone treatment and additional treatment using cal-
cium [11].
Although estrogen receptors and androgen receptors
are present in osteoblasts of both sexes, cortical bone
contains more androgen receptors than trabecular bone
[17,18,19], which provides a possible explanation for the
higher cortical bone mass observed in normal men
compared with women [4]. In addition, it has been
shown that the eﬀects of androgens compared with those
of estrogens are similar on trabecular bone but opposite
on cortical bone of males [20]. Therefore, it is possible
that switching to cross-gender hormones during adult
age leads to diﬀerential changes in bone density
depending on the skeletal site studied, i.e. cortical or
trabecular.
The aim of this cross-sectional study was to explore
the eﬀect of long-term cross-sex hormonal treatment on
cortical and trabecular bone mineral density and main
biochemical parameters of bone metabolism in trans-
sexuals.
Materials and methods
Subjects and sex hormone treatment
Twenty-four M-F transsexuals and 15 F-M transsexuals,
who were controlled regularly in the Outpatient
Department of Gynecologic Endocrinology and Repro-
ductive Medicine of the University Hospital of Berne
between 1973 and 2000 and who showed normal hor-
mone status and phenotype according to their genetic sex
prior to cross-sex hormone treatment participated to this
cross-sectional study (Table 1). All participants gave
their prior written informed consent and the study was
approved by the Hospital Ethical Review Board.
M-F transsexuals
Before surgery, sex reassignment had been initiated with
a ﬁxed combination of an antiandrogen with a synthetic
estrogen (cyproterone acetate 2 mg/day and ethinyl
estradiol 35 lg/day; Diane 35, Schering AG, Germany)
or a free combination of the same compounds [cypro-
terone acetate 2 mg/day (Androcur) and ethinyl estra-
diol 35–100 lg/day (Progynon C or Lynoral, Schering
AG, Germany)]. Surgery consisted of diﬀerent recon-
struction techniques, the choice being dependent on
general health, physical, anatomical and psychological
characteristics of the individual patient. All patients
underwent orchidectomy, eventually followed by peni-
sectomy and vaginoplasty usually in combination with
clitoroplasty and implantation of breast implants. After
surgery, cross-sex hormone treatment was continued
using estradiol valerate (Progynova; Schering AG,
Germany) or micronized 17-beta estradiol (Estrofem;
Novo Nordisk) 2–4 mg/day.
F-M transsexuals
Sex reassignment had been initiated with parenteral
testosterone esters (Testoviron Depot; Schering AG)
250 mg every 3 weeks IM before surgery, which was
continued at the same posology after surgery. Surgery
consisted of hysterectomy, ovariectomy and bilateral
mastectomy in all patients, while surgical penis recon-
struction was inconsistently reported.
Table 1 Clinical characteristics of 24 male-to-female (M-F) and 15
female-to-male (F-M) transsexuals. Results given as med-
ian±MAD (range). BMI body mass index,MAD median absolute
deviation
Transsexuals
M-F F-M
Age, years 44.4±7.7 (29.8–67.9) 34.4±5.6 (25.6–53.3)*
Age at
surgery, years
30.0±6.0 (21.1–62.5) 23.5±3.5 (18.1–37.1)
Height, cm 174.5±3.5 (162.0–182.0) 166.0±3.0 (149.0–172.0)*
Weight, kg 77.2±12.2 (50.0–115.0) 60.2±8.0 (49.0–78.5)*
BMI, kg/m2 25.6±3.4 (15.4–37.1) 25.0±2.6 (20.9–27.6)
Treatment, years
Pre-surgery 2.1±0.7 (0.7–8.7) 1.3±0.3 (0.5–3.7)*
Post-surgery 9.7±4.6 (1.0–24.0) 6.1±3.4 (1.8–22.9)
Total 12.5±4.7 (4.7–24.7) 7.6±3.8 (2.8–24.0)
*P<0.01 F-M vs M-F
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Dual energy X-ray absorptiometry (DXA)
Bone mineral density (BMD) was measured at distal
tibial diaphysis (TDIA), a predominantly cortical site,
and distal tibial epiphysis (TEPI), an area containing a
substantial amount of trabecular bone, using dual-en-
ergy X-ray absorptiometry (DXA; Hologic QDR
4500A, Hologic Inc., Bedford, Mass., USA). Bone
mineral density measurement at distal tibia is a stan-
dardized method established earlier by our group [21].
Brieﬂy, the region of interest (ROI) is deﬁned as the area
of 120 mm height and 129 mm width, starting 10 mm
above the top of the ankle joint space. TEPI corresponds
to the distal 40 mm of the ROI while TDIA corresponds
to the proximal 40 mm of this ROI [21]. In addition
BMD was measured at the lumbar spine (LS, second to
fourth lumbar vertebra), the total hip (HIP) and the
whole body (WB). For more detailed analysis of HIP the
following subregions were analyzed: femoral neck (FN),
intertrochanteric region (INTER), trochanter (TROC),
Ward’s triangle (WARD). Peripheral bone measure-
ments were carried out at the non-dominant limb. Scan
acquisition and analysis were performed using standard
software procedures supplied by the manufacturer
(software version 8.17).
BMD was expressed as g/cm2 of hydroxyapatite and
as Z-scores (SD from the mean of a healthy population
of the same age), both, for the genetic and the pheno-
typic gender. A population of 400 normal Caucasian
women and men, 20–80 years of age, living in the area of
Berne, served as reference. Peak bone mass (mean va-
lue±SD) derived from that female and male reference
population is 1.078±0.131, and 1.100±0.139 g/cm2 at
LS, 0.835±0.100, and 0.937±0.121 g/cm2 at FN,
1.278±0.116, and 1.375±0.118 g/cm2 at TDIA,
0.763±0.094, and 0.927±0.119 g/cm2 at TEPI. Quality
control by means of daily measurement of the anthro-
pomorphic spine phantom supplied by the manufacturer
revealed a precision error of 0.3%, (CV, coeﬃcient of
variation). The mean precision error of DXA measure-
ments in our hands was 1.0% (LS, HIP, WB), and 1.4%
(TDIA, TEPI) in vivo.
Biochemical parameters and assays (for reference
ranges, see Table 5)
Serum measurements
Fasting venous blood samples were taken in the morn-
ing. Serum concentrations of total calcium (Ca total),
inorganic phosphate (Pi), alkaline phosphatase activity
(AP) and creatinine (Cr) were measured by autoanalyzer
techniques.
Ionized calcium (Ca2+) was measured by ion-selec-
tive electrode (Ciba-Corning Diagnostics Corp., Med-
ﬁeld, Mass., USA). Intact PTH (PTH), osteocalcin,
(OC) and insulin-like growth factor-1 (IGF-1) were
measured by two-site immunoradiometric assay (Nic-
hols Institute, San Juan Capistrano, Calif., USA). 25-
Hydroxyvitamin D3 (25-OH-D3) and insulin-like growth
factor-binding protein-3 (IGFBP-3) were measured by
competitive protein-binding RIA (Nichols).
Thyroid stimulating hormone (TSH) was measured by
AxSYM Ultrasensitive II microparticle enzyme immu-
noassay (Abbott, Abbott Park, Ill., USA). Estradiol (E2;
ESTR-US-CT, CIS bio international, Gif-sur-Yvette
Cedex, France) and free testosterone (fT; Coat-a-Count,
Diagnostic Products Corporation, Los Angeles, Calif.,
USA) were measured by RIA. Luteinizing hormone
(LH) and follicle stimulating hormone (FSH) were
measured by electrochemiluminescence immunoassay
(Elecsys; Roche Diagnostics GmbH, Mannheim,
Germany). Manufacturers’ reference ranges were used.
Urine measurements
Fasting 2-h urine samples were analyzed for Ca and Cr
by autoanalyzer techniques. Urinary hydroxyproline
(OH-Pro) was measured using a Hypronosticon kit
(Organon Teknika, Boxtel, The Netherlands). Urinary
Ca and OH-Pro excretion were expressed as ratios to Cr
(Ca/Cr and OH-Pro/Cr). Manufacturers’ reference ran-
ges were used.
Statistics
The studied populations showed non-normal distribu-
tions and/or unequal variances of data. A conservative
data analysis approach was chosen to maximize the
robustness of the statistical signiﬁcances observed,
eventually at the expense of an increased risk of type 2
error and a parallel loss in study power. Medians and
median absolute deviations (MAD) were calculated and
non-parametric tests were chosen for analysis. Mann-
Whitney rank sum tests were performed to assess a
signiﬁcant median diﬀerence between M-F and F-M
results. One sample sign tests were performed to test for
signiﬁcance between the median Z-scores of the study
population versus normal controls of the same genetic
and the same phenotypic gender, respectively. Simple
regression was performed to study the inﬂuence of total
treatment duration on Z-scores and to test for correla-
tions between BMD Z-scores and LH and FSH serum
values. Multiple regression analysis was performed to
study the respective eﬀects of age and total treatment
duration on biochemical parameters of bone metabolism
and bone mineral density. Signiﬁcance levels were set
using the Bonferroni correction to compensate for
multiple testing.
Results
Detailed characteristics of the study population are given
in Table 1. Detailed BMD results expressed as median
Z-scores are shown in Tables 2, 3 and 4 and Fig. 1.
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Detailed results of laboratory parameters of bone turn-
over and sexual endocrinology are shown in Table 5.
M-F transsexuals
M-F transsexuals had a median age of 44.4 years and
were treated by cross-sex hormone treatment during
median 2.1 years before surgery and 9.7 years after
surgery (Table 1). As compared with normal male (ge-
netic) age-matched controls, BMD values measured at
all sites were not signiﬁcantly diﬀerent. As compared to
normal female (phenotypic) age-matched controls,
BMD values at TDIA and WB showed a signiﬁcantly
higher median Z-score (P<0.01, Tables 2, 3 and 4). The
detailed analysis of the HIP and its four subregions
showed no signiﬁcant diﬀerences in BMD values versus
genotypic and phenotypic controls (Tables 2, 3 and 4).
Five M-F transsexuals had osteoporosis as deﬁned
according to the WHO (Fig. 1), i.e. a T-score (SD from
genotypic peak bone mass) below )2.5 SD at least at
one site measured [4].
All biological parameters of bone metabolism (Ta-
ble 5) were within normal range. Cross-sex hormonal
treatment with estrogens was reﬂected by median estra-
diol values at the upper limit of the phenotypic normal
range and within a large scatter ranging from below
normal range (37 pmol/l) to 45 times the upper limit of the
normal range (8140 pmol/l). Median FSH values were
elevated, corresponding to a broad range of estradiol
values. LH and FSH values were signiﬁcantly correlated
with the BMD genotypic Z-scores at the LS (r=0.51,
P=0.014 and r=0.60, P=0.003 respectively) but no
correlation was found with other measurement sites.
F-M transsexuals
F-M transsexuals had a median age of 34.4 years and
were treated by cross-sex hormones during median 1.3
years before surgery, which was continued for 6.1 years
after surgery (Table 1). F-M transsexuals had signiﬁ-
cantly higher median Z-scores compared with female
(genetic) age matched controls at TDIA, TEPI and WB
(+1±0.4 SD, +0.9±0.2 SD, and +1.4±0.3 SD,
respectively, P<0.0001 for all), whereas Z-scores at LS
and HIP, including the hip subregions were not signiﬁ-
cantly diﬀerent. As compared to normal male (pheno-
typic) age-matched controls, Z-scores were not
signiﬁcantly diﬀerent, except for lower values at TEPI
()0.6±0.4 SD, P<0.01, Tables 2, 3 and 4).
All biological parameters of bone metabolism were
within normal range (Table 5). Cross-sex hormonal
treatment with androgens was reﬂected by elevated
median testosterone values for women but within the
normal range for men, the scatter ranging from low
values of 2 pmol/l to values at 1.5 times the upper limit
for normal men (194 pmol/l). Median FSH values were
elevated, corresponding to the broad range of testos-
terone values. LH and FSH values did not correlate ei-
ther with the BMD genotypic Z-scores at the LS
(r=0.04, P=0.87, and r=0.1, P=0.73, respectively) or
at any other measurement site.
Comparison between M-F and F-M transsexuals
In this study, M-F transsexuals were signiﬁcantly older,
taller, heavier and had a signiﬁcantly longer duration of
Table 2 Absolute BMD values (g/cm2) at various skeletal sites of 24
male-to-female (M-F) and 15 female-to-male (F-M) transsexuals
(median±MAD). MAD median absolute deviation
M-F F-M
Lumbar spine (LS) 1.056±0.137 1.075±0.088
Total hip (HIP) 0.909±0.124 0.970 ±0.071
Femoral neck (FN) 0.774±0.095 0.842±0.058
Trochanter (TROC) 0.716±0.097 0.764±0.046
Intertrochanteric region (INTER) 1.049±0.154 1.132±0.106
Ward’s triangle (WARD) 0.593±0.141 0.743±0.046
Tibial diaphysis (TDIA) 1.424±0.100 1.381±0.052
Tibial epiphysis (TEPI) 0.831±0.123 0.825±0.024
Whole body (WB) 1.216±0.098 1.179±0.035
Table 3 BMD Z-scores at various skeletal sites of 24 male-to-
female (M-F) and 15 female-to-male (F-M) transsexuals (median±
MAD). Z-score vs genotypic controlsa. MAD median absolute
deviation
M-F F-M
Lumbar spine (LS) 0.2±0.9 0.4±0.7
Total hip (HIP) )0.5±0.9 0.4±0.5
Femoral neck (FN) )0.2±1.0 0.3±0.5
Trochanter (TROC) )0.3±0.8 1.0±0.6
Intertrochanteric region (INTER) )0.6±0.8 0.3±0.6
Ward’s triangle (WARD) )0.1±0.7 0.3±0.6
Tibial diaphysis (TDIA) 0.6±0.8 1.0±0.4**
Tibial epiphysis (TEPI) )0.3±0.9 0.9±0.2**
Whole body (WB) 1.1±1.1 1.4±0.3**
avs normal controls of the same genetic gender (M-F vs M and F-M
vs F)
**P<0.0001 vs age-matched normal controls
Table 4 BMD Z-scores at various skeletal sites of 24 male-to-
female (M-F) and 15 female-to-male (F-M) transsexuals (median±
MAD). Z-score vs phenotypic controlsa. MAD median absolute
deviation
M-F F-M
Lumbar spine (LS) 0.4±0.9 0.3±0.7
Total hip (HIP) 0.3±1.2 )0.3±0.5
Femoral neck (FN) 0.2±1.2 )0.1±0.5
Trochanter (TROC) 0.3±1.3 0.2±0.6
Intertrochanteric region (INTER) 0.1±1.0 )0.2±0.5
Ward’s triangle (WARD) 0.2±0.9 0.1±0.5
Tibial diaphysis (TDIA) 1.7±1.0* 0.1±0.4
Tibial epiphysis (TEPI) 1.3±1.4 )0.6±0.3*
Whole body (WB) 1.8±1.1* 0.7±0.4
avs normal controls of the same phenotypic gender (M-F vs F and
F-M vs M)
*P<0.01 vs age-matched normal controls
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pre-surgery cross-sex hormonal treatment than F-M
transsexuals (Table 1). They showed larger interindi-
vidual variability in Z-scores than F-M transsexuals;
however, the diﬀerences in BMD between M-F and F-M
transsexuals were not signiﬁcant at any site measured
(all P>0.25, Tables 2, 3 and 4). Total duration of cross-
sex hormone treatment inﬂuenced the Z-score of tibial
diaphysis in M-F transsexuals only: each treatment year
caused a decrease by 0.1 SD (r2=0.19, P=0.04). At
other measurement sites, no similar inﬂuence was de-
tected.
F-M transsexuals had signiﬁcantly higher IGF-1 and
testosterone levels (P<0.001), as compared to M-F
transsexuals. All other parameters of bone metabolism
were not signiﬁcantly diﬀerent between F-M and M-F
transsexuals and within normal ranges.
Discussion
This study explores the eﬀect of long-term cross-sex
hormonal treatment in male-to-female (M-F) and fe-
male-to-male (F-M) transsexuals on the bone mineral
Fig. 1 Individual BMD values at peripheral and central measure-
ment sites compared to mean±1 SD values for normal genotypic
controls (male for M-F transsexuals and female for F-M
transsexuals, shaded area) and normal phenotypic controls (female
for M-F transsexuals and male for F-M transsexuals, area between
the lines). The dotted line represents the cut-oﬀ value of T-score
)2.5 SD
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density of sites with substantial amount of cortical bone
(TDIA and WB), sites with predominantly trabecular
bone (TEPI, TROC, WARD, LS) and sites with bal-
anced repartition of cortical and trabecular bone (IN-
TER, FN), as well as on markers of bone metabolism.
The M-F/F-M ratio of transsexuals controlled in the
outpatient department of gynecologic endocrinology
and reproductive medicine of the University Hospital of
Berne is approximately 3:2. A corresponding ratio of
almost 3:1 has been reported earlier, considering 95% of
the Dutch population of transsexuals [16].
Usually, male BMD values exceed those of females,
as indicated by our reference ranges. Whereas in
peripheral bones, such as the tibia, those gender diﬀer-
ences are larger, they tend to be smaller at the hip and
almost negligible at the lumbar spine. Similar ﬁndings
were published earlier [22,23].
F-M transsexuals
Due to the cross-sectional design of this study, the ob-
served eﬀects of androgens on bone in F-M transsexuals
could be simply due to a selection bias, e.g. by assuming
that women undergoing sex reassignment would be taller
or heavier than average women in Switzerland. Based on
the most recent data of the Swiss Federal Oﬃce for
Statistics in 1997 (mean±SD), the average height and
weight for Swiss women aged 25–34 and 35–44 years is
165.7±6.2 and 164.4±6.3 cm, respectively, and
58.7±9.4 and 60.3±9.7 kg, respectively (personal
communication from Dr. Wu¨est, Bundesamt fu¨r Statis-
tik, Bern, Switzerland). At a median age of 35±4.5
years, the women included in our normative database
for BMD measurements had a median height of
165±4 cm and a median weight of 59±5 kg. These data
compare well with the calculated medians±MAD of
F-M transsexuals in this study: 166.0±3.0 cm and
60.2±8.0 kg at a median age of 34.4±5.6 years.
Androgens have been shown to promote bone growth
and by the end of puberty, men have greater bone mass
and greater cortical diameter than women
[24,25,26,27,28]. In addition, it has been observed that
long bone dimensions continue to increase during
adulthood in men, presumably in relationship with
periosteal bone apposition [29]. In the present study and
in contrast, no signiﬁcant correlation was found between
age or duration of cross-sex hormone treatment and
bone area measured at any site (data not shown). In this
cross-sectional study, F-M transsexuals under cross-sex
hormone treatment had higher bone density values than
women at tibia and WB. The magnitude of this in-
creased BMD was such that they compared favorably
with men, with the exception of TEPI. These observa-
tions are in favor of a cortical eﬀect of androgen treat-
ment in F-M transsexuals. However, these potential
androgenic eﬀects on cortical bone were not found at the
HIP and its diﬀerent subregions or at the LS, possibly in
relation with the increasing proportion of trabecular
bone. Androgens may exert an inhibitory eﬀect on bone
resorption [30] as well as a stimulation of bone forma-
tion [31] via cytokines and IGF-1. IGF-1 has been
shown to have potent actions on bone and its serum
levels are increased by androgens [32]. In addition in the
present study, F-M transsexuals had signiﬁcantly higher
serum IGF-1 levels than M-F transsexuals, which may
Table 5 Parameters of bone metabolism in serum and urine of 24
male-to-female (M-F) and 15 female-to-male (F-M) transsexuals.
Results given as median±MAD (range). Normal range of males
and females. Ca calcium, Ph phosphate, Cr creatinine, AP alkaline
phosphatase, IGFBP-3 insulin-like growth factor-binding protein-
3, E2 17b-estradiol, OH-Pro hydroxyproline
Transsexuals Normal range
M-F F-M Males Females
Serum
Ca total, mmol/l 2.33±0.08 (2.18–2.53) 2.38±0.02 (2.32–2.52) 2.10–2.55 2.10–2.55
Ca ionized, mmol/l 1.19±0.04 (1.08–1.30) 1.21±0.03 (1.07–1.29) 1.15–1.30 1.15–1.30
Ph, mmol/l 1.15±0.12 (0.76–1.49) 1.05±0.08 (0.69–1.23) 0.74–1.55 0.74–1.55
Cr, lmol/l 80±10 (58–116) 90±6 (61–103) 59–116 45–102
AP, IU/l 63±15 (32–159) 61±13 (37–106) 36–108 36–120
Osteocalcin, ng/ml 5.0±1.0 (2.3–9.1) 6.3±1.5 (3.4–11.4) 2.3–13.8 1.2–10.5
25-OH-D3, ng/ml 18±7 (4–52) 23±5 (12–43) 6–40 6–40
Intact PTH, pg/ml 41±9 (13–56) 31±6 (17–54) 10–65 10–65
TSH, mIU/l 2.12±0.41 (1.03–3.50) 1.75±0.63 (0.25–4.87) 0.35–4.50 0.35–4.50
IGF-I, ng/ml 125±41 (29–253) 226±31 (142–274)* 48–400 48–400
IGFBP-3, lg/ml 3.83±0.37 (1.76–5.67) 4.22±0.87 (2.76–5.43) 1.15–5.18 1.19–5.43
LH, IU/l 4±3 (1–37) 8±7 (1–49) 3–16 3–14
FSH, IU/l 14±11 (1–102) 36±25 (1–135) 2–9 2–8
E2, pmol/l 142±105 (37–8140) 58±21 (37–314) 55–165 110–183
Testosterone, pmol/l 2±0 (2–4) 57±46 (2–194)* 38–142 1–11
Urine
Ca/Cr 0.22±0.07 (0.07–1.06) 0.24±0.15 (0.07–0.60) <0.45 <0.45
OH-Pro/Cr 0.012±0.006 (0.003–0.038) 0.018±0.006 (0.005–0.033) <0.025 <0.025
Signiﬁcance by Wilcoxon rank sum test: *P<0.001, F-M vs M-F
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be the result of the androgen therapy and explain, at
least in part, the gain in cortical bone observed at the
tibia and the whole body. The correlation of IGF-1
levels with BMD values in men and women has been
shown in some publications [33,34], while other publi-
cations reported the absence of correlation [35] or a
correlation in men only [36]. In the present study with
M-F and F-M transsexuals, no correlation could be
established between BMD values, IGF-1 values and
serum testosterone levels.
M-F transsexuals
M-F transsexuals were treated with an antiandrogen and
estrogens. The estrogen dosage used after surgery was
generally higher than the one used in genetic women
suﬀering from early menopause. The BMD results sug-
gest preservation at all sites over a median duration of
cross-sex hormone treatment of 12.5 years, with BMD
results not signiﬁcantly diﬀerent from the genetic (male)
reference range. Furthermore, BMD Z-scores at the
tibial diaphysis and the whole body, both representing
mainly cortical bone, were signiﬁcantly higher in M-F
transsexuals than in normal women, indicating that the
higher peak bone mass acquired during puberty [24,28]
was maintained by estrogens despite anti-androgen
treatment. Serum FSH and LH values were signiﬁcantly
correlated with Z-scores measured at the lumbar spine.
This ﬁnding reinforces the importance of these two
biochemical parameters as potential surrogates repre-
senting the outcome of successful sex hormone replace-
ment therapy in M-F transsexuals [15]. The IGF-1
values were signiﬁcantly lower than in F-M transsexuals
treated with androgens, remained however within the
normal range. In a cross-sectional study in M-F trans-
sexuals, potential suppression of bone resorption after
cross-sex hormonal treatment of 24 months median
without associated bone loss as assessed by histo-
morphometry and biochemical parameters was reported
by Lips et al. [12]. Decreased bone turnover and IGF-1
levels with subsequent increase in lumbar spine BMD
were documented by the same group after one year of
cross-sex hormonal treatment in M-F transsexuals [14].
A long-term follow-up over 32–63 months of cross-sex
hormonal treatment conﬁrmed a continuing decrease of
bone turnover, but failed to conﬁrm the signiﬁcant in-
crease in lumbar spine BMD observed in the ﬁrst year
[15]. Goh et al. demonstrated that Singaporean ovari-
ectomized F-M transsexuals had a signiﬁcantly higher
lumbar spine BMD after 1–3 years of androgen treat-
ment than age-matched female controls and that lumbar
spine BMD increased if androgens were resumed in
those genetically female individuals who had stopped
hormonal substitution [11]. Vered et al. demonstrated
increased lumbar spine and femoral neck BMD in a 39-
year-old XY female with complete androgen insensitiv-
ity after treatment with conjugated estrogens for 4 years
and in a 37-year-old XX male with 11b-hydroxylase
deﬁciency treated with testosterone for 27 months. The
authors concluded that phenotypically matched sex
hormone therapy was essential not only to maintain
external appearance, but also for the preservation of
bone mass [37].
In the present study, large interindividual variations
in bone mineral density were observed in M-F trans-
sexuals: ﬁve subjects had a BMD genotypic T-score
below )2.5 SD at least at one site of measurement and
therefore had osteoporosis according to the WHO deﬁ-
nition. All ﬁve patients had low estradiol levels and
elevated FSH values, indicating that compliance with
their treatment with sex hormones was inappropriate.
Another ﬁnding was that a limited number of M-F
transsexuals were taking more estrogens than needed for
preservation of bone. Although their FSH levels were
almost totally suppressed and their estradiol levels as
high as 35 times the upper limit of the normal range,
their IGF-1 and BMD values were within normal range.
Our study has several limitations. It was a cross-sec-
tional observational study. However, the subjects were all
treated with the same cross-sex hormone treatment reg-
imen and followed over up to 24 years after sex reas-
signment surgery. This study was explorative by nature
and one of its goals was to generate hypotheses for pro-
spective longitudinal trials. The data analysis strategy
was deﬁned in order to maximize the robustness of the
statistical signiﬁcances observed (Bonferroni correction,
use of non-parametric statistical tests), which occurred at
the expense of an increased risk of type two error and a
parallel loss in study power. We may therefore have
missed some statistically signiﬁcant correlations or dif-
ferences between groups. However, and considering the
diﬃculties in realizing a prospective trial with transsex-
uals to test newly generated hypotheses, the conservative
analysis of the present data would be expected to maxi-
mize the chances to conﬁrm these ﬁndings.
The increased BMD observed at the tibia in F-M
transsexuals with long term cross-sex hormonal treat-
ment with testosterone might have been inﬂuenced by
testosterone-induced modiﬁcations in bone size [27]. The
number of included patients was too small to identify
signiﬁcant changes in bone area with age or duration of
cross-sex hormone treatment at any site. Another
appealing approach would have been the calculation of
volumetric BMD based on simple models of bone shape
[38], which could have brought interesting new insights if
more consistent data on bone area would have been
available. In addition, this study was not designed to
systematically record lifestyle parameters, which may
inﬂuence BMD or biochemical parameters of bone
metabolism (e.g. physical activity level, alcohol con-
sumption, smoking etc.), which might have acted as
possible confounders. However, all biochemical values
of calcium phosphate metabolism parameters were
within normal ranges and comparable across groups.
In transsexual genetic males and females under long
term cross-sex hormone treatment, BMD values are
generally preserved or increased. Non-compliance with
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cross-sex hormone treatment may lead to low BMD,
which in this study was observed only in genetic males.
IGF-1 could play a role in the mediation of the eﬀect of
androgens on bone in F-M transsexuals.
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